STAA staar.com: Company Value to Revenue

Official company branding of STAAR Surgical (STAA)

STAAR Surgical Company (STAA) maintains high operating margins and stable cash flow based on its technological leadership in lens manufacturing. The EV/Sales ratio reflects market expectations, with the indicator reaching 3301.52. A loyal team of R&D specialists drives innovation, although final demand is influenced by aesthetic medicine cycles, causing patients to postpone surgeries during recessionary periods.

staar.com (STAA): Enterprise Value-to-Revenue Ratio from 11/23/2025 to 11/20/2026

STAA (STAAR Surgical Co): analytical breakdowns and indicator data

- current quotes and average value forecast:
- cash balance and cash flow data:
Initial company analysis:STAA (STAAR Surgical)
Manufactured products of STAAR Surgical Corp

This indicator determines the market value of the business, accounting for net debt relative to generated revenue. The EV/Sales multiple trend helps identify hidden asset overvaluation when market expectations are inflated. The calculation excludes the influence of borrowing structures, focusing instead on the actual value of operating assets. For STAAR Surgical Company (STAA), such a valuation confirms the efficiency of owning lens production. Control over key technologies reduces vendor risks, stabilizing the company's fundamental value.

Direct competitors

ISRG - EV/Sales Multiple|DHR: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple BD (BDX)|Enterprise Value-to-Revenue Ratio STERIS plc|Company Value to Revenue Ratio WST (West Pharmaceutical Services)|Company Value to Revenue BAX (Baxter Corp)|Masimo - Company Value to Revenue Ratio|Stevanato Group S.p.A. - Company Value to Revenue|Total Company Value-to-Revenue Ratio Teleflex Inc (TFX)|MMSI - Enterprise Value-to-Revenue Ratio|Total Company Value-to-Revenue Ratio Envista Holdings Corp NVST|ICUI: EV/Sales Multiple|Company Value to Revenue Ratio XRAY|LMAT (LeMaitre Corp) - EV/Sales Multiple|ATRC (AtriCure Inc) - Enterprise Value-to-Revenue Coefficient|Enterprise Value-to-Revenue Ratio ChromaDex (NAGE)|Company Value to Revenue ZimVie Inc. ZIMV|EV/Sales Multiple ANGO (angiodynamics.com)|EV/Sales Multiple cerus.com CERS|teknova.com - EV/Sales Multiple|Enterprise Value-to-Sales Ratio Monogram Technologies Inc. (MGRM)|Sharps Technology, Inc. (STSS) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple InfuSystem Inc (INFU)|UTMD (Utah Medical Products Inc.) - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple KORU Medical Systems KRMD|Enterprise Value-to-Revenue Ratio Nyxoah SA (NYXH)|Enterprise Value-to-Revenue Coefficient MBOT|EV/Sales Multiple PDEX (Pro-Dex Inc.)|Enterprise Value-to-Revenue Coefficient ZTEK (Zentek Limited)|elutia.com - EV/Sales Multiple|Business Value to Revenue MLSS (milestonescientific.com)|NXGL (NEXGEL Inc.) - Company Value to Revenue|Retractable Technologies - Business Value to Revenue|Enterprise Value-to-Revenue Ratio harvardbioscience.com|Femasys Corp (FEMY) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple MHUA|Predictive Oncology Inc. - Company Value to Revenue Ratio|EV/Sales Multiple CJMB (Callan JMB Inc)|EV/Sales Multiple Atrion Corp ATRI|NeuroMetrix Corporation - EV/Sales Multiple